OverviewChartTechnicalNewsTraderScreen

CytomX Therapeutics Inc/  US23284F1057  /

NASDAQ
03/05/2024  22:15:00 Chg. -0.0700 Volume Bid01:59:55 Ask01:59:55 High Low
4.4300USD -1.56% 11.09 mill.
Turnover: 44.45 mill.		 4.6700Bid Size: 2,000 4.7000Ask Size: 14,000 5.0600 4.4300
GlobeNewswire 01/05 CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...
GlobeNewswire 08/04 CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Dire...
GlobeNewswire 03/04 CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engag...
GlobeNewswire 21/03 CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
GlobeNewswire 18/03 CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Col...
GlobeNewswire 11/03 CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
GlobeNewswire 05/03 Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expande...
GlobeNewswire 05/03 Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expande...
GlobeNewswire 04/03 CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
GlobeNewswire 27/02 CytomX Therapeutics to Present at Upcoming March Investor Conferences
GlobeNewswire 24/01 CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Dru...
GlobeNewswire 12/01 CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference
GlobeNewswire 04/01 CytomX Therapeutics Outlines 2024 Company Priorities and Milestones
GlobeNewswire 21/12/2023 CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 07/11/2023 CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire 01/11/2023 CytomX Therapeutics to Present at Upcoming November Investor Conferences
GlobeNewswire 31/10/2023 CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023
GlobeNewswire 30/10/2023 CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at t...
GlobeNewswire 18/10/2023 CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 a...
GlobeNewswire 05/09/2023 CytomX Therapeutics to Present at Upcoming September Investor Conferences
GlobeNewswire 23/03/2022 CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors
GlobeNewswire 17/03/2022 CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program...
GlobeNewswire 01/03/2022 CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Busine...
GlobeNewswire 28/02/2022 CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference
GlobeNewswire 22/02/2022 CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022